Recent reports of ammonia released in high concentrations during cannabis smoking raise concerns about putative neurotoxic effects. Cannabis (54mg) was administered in a double-blind, placebo-controlled design to healthy cannabis users (n=15) either orally, or through smoking (6.9%THC cigarette) or inhalation of heated vaporized cannabis (Volcano®). Serial assay of plasma ammonia concentrations at 0, 2, 4, 6, 8, 10, 15, 30, and 90 minutes from onset of cannabis administration showed significant time [F(8,297)=2.389, P=0.016], and treatment [F(3,297)=6.243, P=0.0004] effects with robust differences between placebo and edible at 30 (p=0.002), and 90 minutes (P=0.007) and between placebo and vaporized (P=0.02) and smoking routes (P=0.01) at 90 minutes. Furthermore, plasma ammonia positively correlated with blood THC concentrations (P=0.03). To test the hypothesis that this delayed increase in plasma ammonia originates from the brain we administered THC (3 and 10mg/kg IP) to mice and measured plasma, liver, and brain ammonia concentrations at 1, 3, 5 and 30 minutes post-injection. Administration of THC to mice did not cause significant change in plasma ammonia concentrations within the first 5 minutes, but significantly reduced striatal glutamine synthetase (GS) activity (p=0.046) and increased striatal ammonia concentration (p=0.016). Furthermore, plasma THC concentration correlated positively with striatal ammonia concentration (p<0.001) and negatively with striatal GS activity (p=0.030). At 30 minute, we found marked increase in striatal ammonia (P<0.0001) associated with significant increase in plasma ammonia (P=0.042) concentration.
In conclusion, the results of these studies demonstrate that cannabis intake caused time and route-dependent increases in plasma ammonia concentrations in human cannabis users and in mice, THC reduced brain GS activity and increased brain and plasma ammonia concentrations.